cultivate(MD) Focus Fund Enhances Early-Stage Medical Device Innovation

On May 11, 2026, cultivate(MD), a prominent venture capital firm specializing in medical devices, announced the deployment of capital through its Focus Fund across four innovative portfolio companies in just the past month. This strategic move reflects the fund's commitment to identify and support early-stage companies that are making waves in the medical device industry.

The Focus Fund represents cultivate(MD)'s fifth investment vehicle and emphasizes a long-term strategy aimed at 2031. The initiative seeks to invest in top-tier early-stage medical device companies, ultimately facilitating their growth and successful exit while addressing significant healthcare needs.

Among the notable investments made by cultivate(MD) is the co-leading of a Series B financing round for Prana Surgical, a company that recently received clearance from the U.S. Food and Drug Administration (FDA) for its innovative Prana System. The funds from this round are earmarked for the U.S. commercialization of this groundbreaking technology, aimed at improving diagnostics and treatment options for small peripheral lung masses.

In addition to Prana Surgical, the Focus Fund made follow-on investments in two pivotal companies: Virtual Incision and SpinTech MRI. Virtual Incision is revolutionizing surgical procedures with its Miniaturized Robotic-Assisted Surgery (miniRAS) system, designed to enhance surgical precision and patient recovery times. Meanwhile, SpinTech MRI offers advanced neurological imaging software, enhancing MRI images to assist neurosurgeons with improved planning for various procedures such as tumor resections and deep brain stimulation.

Moreover, cultivate(MD) is also spearheading a convertible note investment that includes warrant coverage for SentiAR, an augmented reality platform tailored for cardiac electrophysiology procedures. This investment highlights cultivate(MD)’s strategic intent to support technologies that are at the forefront of medical innovation.

R. Sean Churchill, MD, MBA, the Managing Director of cultivate(MD), expressed confidence in the Focus Fund's mission, stating, "In the first two months of its operation, the Focus Fund is delivering on its goals. We are making calculated investments in promising companies that are hitting clinical and regulatory milestones. The recent FDA clearance for Prana Surgical is a significant achievement, particularly for patients seeking enhanced diagnostic options."

Churchill further noted the ongoing evaluation of additional investment opportunities, reflecting cultivate(MD)’s commitment to rigorous criteria for selecting portfolio companies. These criteria include addressing substantial unmet clinical needs, fitting seamlessly into existing clinical workflows, providing a viable path to reimbursement, and demonstrating strong management teams capable of executing products to market successfully.

Investments from the Focus Fund are exclusively open to accredited investors, following strict regulations defined under the Securities Act of 1933. The firm anticipates closing the Focus Fund by December 11, 2026, and potential investors are encouraged to reach out for more information.

In conclusion, cultivate(MD) continues to position itself as a leader in medical device venture capital, focusing on groundbreaking technologies that promise improvements in healthcare delivery and patient outcomes. This latest round of funding not only illustrates the firm's strategic foresight but also highlights the exciting innovations emerging from the medical technology sector.

For more information about the Focus Fund and investment opportunities, visit cultivate(MD).